12:00 AM
Jan 26, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Genzyme sales and marketing update

Genzyme will transition all remaining U.S. patients receiving Renagel sevelamer hydrochloride tablets to its Renvela sevelamer...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >